AMRI reports ‘solid’ results for Q2

Large-scale manufacturing drives growth

AMRI reported ‘solid’ financial and operating results for the second quarter to 30 June, including a US$2.2m improvement in net income compared with Q2 2011.

The US contract manufacturer’s large-scale manufacturing segment continues to drive growth and its aseptic formulation and fill operations in Burlington, US also showed improvement during the quarter.

AMRI’s total contract revenue, from discovery services, development and small-scale and large-scale manufacturing, declined during the quarter by 2% to US$42.4m, compared with the same period in 2011.

Highlights include a winning a contract with Cardium Therapeutics to manufacture sterile pre-filled syringes in support of the US introduction of Excellagen and the expansion of its global medicinal and computational chemistry capabilities in India, complementing existing capabilities in the US and Singapore.

Companies